Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Catalent, Inc. stock logo
CTLT
Catalent
$63.48
$62.87
$58.28
$63.50
$11.52B1.152.08 million shsN/A
Insmed, Inc. stock logo
INSM
Insmed
$163.54
+1.3%
$141.18
$60.40
$166.44
$34.11B1.032.15 million shs2.19 million shs
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$316.15
-1.5%
$323.50
$170.99
$355.30
$35.18B0.31216,808 shs321,353 shs
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
$13.86
+0.4%
$14.83
$12.80
$15.69
$43.91B0.212.65 million shs2.83 million shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Catalent, Inc. stock logo
CTLT
Catalent
0.00%0.00%0.00%0.00%+4.67%
Insmed, Inc. stock logo
INSM
Insmed
-1.56%-0.58%+10.59%+54.30%+114.94%
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
-1.86%-6.05%-1.05%+14.97%+32,093,999,900.00%
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
+0.58%-4.63%-8.70%-6.25%-3.80%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Catalent, Inc. stock logo
CTLT
Catalent
$63.48
$62.87
$58.28
$63.50
$11.52B1.152.08 million shsN/A
Insmed, Inc. stock logo
INSM
Insmed
$163.54
+1.3%
$141.18
$60.40
$166.44
$34.11B1.032.15 million shs2.19 million shs
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$316.15
-1.5%
$323.50
$170.99
$355.30
$35.18B0.31216,808 shs321,353 shs
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
$13.86
+0.4%
$14.83
$12.80
$15.69
$43.91B0.212.65 million shs2.83 million shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Catalent, Inc. stock logo
CTLT
Catalent
0.00%0.00%0.00%0.00%+4.67%
Insmed, Inc. stock logo
INSM
Insmed
-1.56%-0.58%+10.59%+54.30%+114.94%
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
-1.86%-6.05%-1.05%+14.97%+32,093,999,900.00%
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
+0.58%-4.63%-8.70%-6.25%-3.80%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Catalent, Inc. stock logo
CTLT
Catalent
0.00
N/AN/AN/A
Insmed, Inc. stock logo
INSM
Insmed
2.86
Moderate Buy$152.88-6.52% Downside
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
2.90
Moderate Buy$340.307.64% Upside
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
2.00
HoldN/AN/A

Current Analyst Ratings Breakdown

Latest CTLT, TAK, ONC, and INSM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/14/2025
Insmed, Inc. stock logo
INSM
Insmed
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$140.00 ➝ $194.00
10/14/2025
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C+)
10/8/2025
Insmed, Inc. stock logo
INSM
Insmed
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/8/2025
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$345.00 ➝ $385.00
10/8/2025
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/3/2025
Insmed, Inc. stock logo
INSM
Insmed
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$121.00 ➝ $196.00
10/2/2025
Insmed, Inc. stock logo
INSM
Insmed
Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
10/2/2025
Insmed, Inc. stock logo
INSM
Insmed
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$154.00 ➝ $193.00
10/1/2025
Insmed, Inc. stock logo
INSM
Insmed
Evercore ISI
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$180.00
9/27/2025
Insmed, Inc. stock logo
INSM
Insmed
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/27/2025
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
(Data available from 10/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Catalent, Inc. stock logo
CTLT
Catalent
$4.38B2.63$2.64 per share24.04$19.91 per share3.19
Insmed, Inc. stock logo
INSM
Insmed
$363.71M95.05N/AN/A$1.60 per share102.21
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$3.81B9.09N/AN/A$34.10 per share9.27
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
$30.09B1.47$3.19 per share4.34$14.39 per share0.96
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Catalent, Inc. stock logo
CTLT
Catalent
-$1.04B-$2.26N/A47.022.69-9.28%-0.66%-0.24%N/A
Insmed, Inc. stock logo
INSM
Insmed
-$913.77M-$5.71N/AN/AN/A-259.82%-195.37%-49.49%10/30/2025 (Estimated)
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
-$644.79M-$1.73N/A445.28N/A-3.89%-1.22%-0.72%N/A
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
$712.33M$0.3046.188.40N/A3.20%10.50%5.10%10/30/2025 (Estimated)

Latest CTLT, TAK, ONC, and INSM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/30/2025Q3 2025
Insmed, Inc. stock logo
INSM
Insmed
-$1.35N/AN/AN/A$114.33 millionN/A
10/30/2025Q2 2026
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
$0.46N/AN/AN/A$8.01 billionN/A
8/7/2025Q2 2025
Insmed, Inc. stock logo
INSM
Insmed
-$1.30-$1.70-$0.40-$1.70$104.06 million$107.42 million
8/6/2025Q2 2025
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$0.48$0.84+$0.36$0.84$1.24 billion$1.32 billion
7/30/2025Q1 2026
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
$0.47$0.52+$0.05$0.27$7.96 billion$7.45 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Catalent, Inc. stock logo
CTLT
Catalent
N/AN/AN/AN/AN/A
Insmed, Inc. stock logo
INSM
Insmed
N/AN/AN/AN/AN/A
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
N/AN/AN/AN/AN/A
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
$0.553.97%N/A183.33%N/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Catalent, Inc. stock logo
CTLT
Catalent
1.38
2.51
1.96
Insmed, Inc. stock logo
INSM
Insmed
0.45
6.68
6.33
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
0.04
1.95
1.72
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
0.60
1.16
0.59

Institutional Ownership

CompanyInstitutional Ownership
Catalent, Inc. stock logo
CTLT
Catalent
N/A
Insmed, Inc. stock logo
INSM
Insmed
N/A
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
48.55%
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
9.17%

Insider Ownership

CompanyInsider Ownership
Catalent, Inc. stock logo
CTLT
Catalent
0.31%
Insmed, Inc. stock logo
INSM
Insmed
3.00%
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
6.62%
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
0.04%
CompanyEmployeesShares OutstandingFree FloatOptionable
Catalent, Inc. stock logo
CTLT
Catalent
16,900181.51 million180.95 millionOptionable
Insmed, Inc. stock logo
INSM
Insmed
1,271211.38 million205.03 millionOptionable
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
11,000109.60 million102.34 millionN/A
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
47,4553.18 billion3.18 billionOptionable

Recent News About These Companies

J&J in talks to acquire Protagonist Therapeutics
Takeda Opens $170 Million Expansion
Takeda walks away from cell therapy in priority U-turn
Takeda walks away from cell therapy in priority U-turn
Takeda, in reversal, abandons cell therapy research

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Catalent stock logo

Catalent NYSE:CTLT

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was founded in 1933 and is headquartered in Somerset, New Jersey.

Insmed stock logo

Insmed NASDAQ:INSM

$163.54 +2.16 (+1.34%)
Closing price 04:00 PM Eastern
Extended Trading
$163.50 -0.04 (-0.02%)
As of 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

BeOne Medicines stock logo

BeOne Medicines NASDAQ:ONC

$316.15 -4.79 (-1.49%)
As of 04:00 PM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Takeda Pharmaceutical stock logo

Takeda Pharmaceutical NYSE:TAK

$13.86 +0.06 (+0.40%)
Closing price 03:59 PM Eastern
Extended Trading
$13.86 +0.00 (+0.04%)
As of 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.